Tuesday, 29 April 2014

EMA recommends granting a marketing authorisation for trametinib and extending indications for sorafenib

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for trametinib (Mekinist) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The CHMP has also recommended adding a new indication to the use of the cancer medicine sorafenib (Nexavar) to treat patients with papillary/follicular/Hürthle cell thyroid carcinoma, refractory to radioactive iodine. Read more here.

No comments:

Post a Comment